Medical treatment after myocardial infarction. Results of studies using various methods.
Patients who have had myocardial infarction and are at risk for continued problems may benefit from several treatment methods (table 1). Beta-adrenergic blockers reduce subsequent cardiovascular morbidity and mortality through their effect on the myocardial supply-demand balance. Administration of angiotensin-converting enzyme inhibitors reduces morbidity and mortality rates in myocardial infarction survivors who have diminished left ventricular ejection fraction. Aspirin and other anticoagulants are beneficial through their antiplatelet effects. Cardiac rehabilitation methods and aggressive management of lipids levels are also useful.
Smith
L K
LK
Arizona Heart Institute, Phoenix 85006.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003663:Decision Trees; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000517:prevention & control; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D011379:Prognosis; D012307:Risk Factors; D013318:Stroke Volume; D015996:Survival Rate
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D002121:Calcium Channel Blockers